Momenta Pharmaceuticals Inc. (MNTA): Technical Analysis and analyst Ratings


Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) changes shares on Monday trading session, with a change of 14.81% or $4.6 shares. The trading starts at $30.40 and closed at $31.05 throughout the day. The trading session low price was $30.23 and day high was $37.57 on Monday, June 15. After the session, the Healthcare sector daily volume shifted to 4.35 million while its average volume is 1.11M. In other hand, the MNTA market cap reached to $4.14B. While, its current target price is $35.65 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 12.21% and up 19.31% for month. Its quarterly performance was 61.75% above, while its half year performance is up 111.82%. MNTA yearly performance stood at positive 197.58% and rise 80.69% for year-to-date. Current recommendation for Momenta Pharmaceuticals Inc. is 2.30.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. MNTA EPS (TTM) for 12-month is -2.80. EPS for this year is -29.10%, while for the next year its value is -1.85. Its EPS Q/Q reached 26.00%. It has an EPS of -8.90% down for past five years.

Let’s take a look on the analyst recommendations on MNTA for the current month and previous month. For the current month, 6 of 11 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 4 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $29.00-$50.00. Average target price for MNTA was reached at $42.11.

Blackrock Inc., FMR, LLC and Vanguard Group, Inc. (The) are the top three holders in Momenta Pharmaceuticals Inc. (MNTA) stock. On Mar 30, 2020, Blackrock Inc. has 18.22 million shares which valued 495.52 million. On Mar 30, 2020, FMR, LLC owned 17.59 million shares which valued at 478.48 million. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 12.24 million shares which valued at 332.99 million. In the end, Vanguard Group, Inc. (The) have 10.40% shares outstanding of Momenta Pharmaceuticals Inc. (MNTA) on Mar 30, 2020. The insider ownership moved to 0.30% and institutional holding shifted to 100.00%.

The company posted an EPS (TTM) of -2.80. According to the most recent quarter report on (Jun 2020), 9 analysts estimated an average EPS of -0.41, while -1.16 EPS posted a year ago period. Analyst Estimated EPS for MNTA published in the report was -0.49–0.34 during the same period. Comparing with last year, the average estimated EPS was -1.16 which is lower than -0.34 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for MNTA rise 54.34% for period of 200 days. SMA for 50 days was 15.79% which is showing green signal, while SMA-20 was 12.85%. The moving average value for Momenta Pharmaceuticals Inc. (MNTA) is 27.40 and 31.86 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in MNTA stock. On Jun 12, WHEELER CRAIG A, President & CEO, sold 37,575 trading shares at the cost of $30.56, which valued at 1.15 million. On Jun 12, FIER IAN, Chief Mfg and Program Officer, sold 6,756 shares at the cost of $30.15, with total shares of 15,934. On Jun 12, BELTRAMELLO JO ANN, Chief HR and Inf. Officer, sold 6,756 shares at the cost of 30.15. After this transaction, BELTRAMELLO JO ANN total shares reached to 57,003 which valued at 0.2 million.